EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19

Karan Srisurapanont, Kasama Manothummetha, Nirada Siriyakorn, Mary G Bowring, Lucy X Li, Willa V Cochran, Cory A Schulz, Sean Ellis, Kanin Thammavaranucupt, Daniel C Brennan, Robin K Avery, William A Werbel und 1 weitere

JAMA Network Open · 28.07.2026 · 9 (7) · e2625591

DOI: 10.1001/jamanetworkopen.2026.25591 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Network Open, online erschienen am 28.07.2026. Verfasst von Karan Srisurapanont und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, Kidney Transplantation, Antiviral Agents. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The efficacy and safety of remdesivir for COVID-19 in kidney transplant (KT) recipients across evolving pandemic eras remain unclear.

Objective

To compare clinical outcomes among adult KT recipients with symptomatic COVID-19 who received early remdesivir vs those who did not receive remdesivir. Design, Setting, and Participants This retrospective cohort study emulated a target trial using observational data from 5 hospitals within the Johns Hopkins Health System. Adult KT recipients (aged ≥18 years) with a functioning allograft and symptomatic COVID-19 from March 2020 through January 2024 were eligible. Patients who received anti–SARS-CoV-2 monoclonal antibodies, nirmatrelvir-ritonavir, and/or molnupiravir were excluded. Follow-up continued for up to 1 year after COVID-19 diagnosis. Exposures Individuals who initiated remdesivir within 7 days of diagnosis and received at least 3 consecutive days of therapy were assigned to the early remdesivir strategy, whereas those who did not receive remdesivir were assigned to the no remdesivir strategy. Main Outcomes and Measures The primary outcome was all-cause graft loss (ACGL), a composite of graft failure and all-cause mortality. Secondary outcomes included all-cause mortality, cardiovascular events (CVEs), and long COVID. Per-protocol associations were estimated using a clone-censor-weight (CCW) approach with weighted Cox proportional hazards marginal structural regression models and robust SEs to calculate hazard ratios (HRs) and 95% CIs.

Results

Among 432 KT recipients with symptomatic COVID-19 (median age, 57 years [IQR, 46-66 years]; 248 [57.4%] were male), 177 (41.0%) initiated early remdesivir and 255 (59.0%) received no remdesivir. Over 1 year of follow-up, early remdesivir initiation vs no remdesivir was associated with a lower risk of ACGL (HR, 0.53; 95% CI, 0.31-0.92) and CVEs (HR, 0.58; 95% CI, 0.35-0.98) after CCW adjustment. There was no significant association between early initiation of remdesivir and lower risk of all-cause mortality (HR, 0.51; 95% CI, 0.24-1.06) or long COVID (HR, 0.65; 95% CI, 0.21-2.05) in the weighted analysis. Conclusions and Relevance In this target trial emulation, KT recipients with symptomatic acute COVID-19 who underwent early remdesivir treatment had reduced risk of ACGL and CVEs. These findings suggest that prompt initiation of remdesivir during COVID-19 illness may protect kidney allograft survival and cardiovascular health in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlanineAdenosine MonophosphateKidney TransplantationAntiviral AgentsCOVID-19 Drug TreatmentGraft RejectionCOVID-19HumansMiddle AgedRetrospective StudiesFemaleMaleSARS-CoV-2AgedAdult

Substanzen

remdesivirAlanineAdenosine MonophosphateAntiviral Agents

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Department of Medicine, University of Miami/Jackson Memorial Hospital, Miami, Florida.
  • Department of Medicine, Rajavithi Hospital, Bangkok, Thailand.
  • Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Johns Hopkins Comprehensive Transplant Center, Baltimore, Maryland.
  • Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.

Zitieren

APA

Srisurapanont, K., Manothummetha, K., Siriyakorn, N., Bowring, M. G., Li, L. X., Cochran, W. V., Schulz, C. A., Ellis, S., Thammavaranucupt, K., Brennan, D. C., Avery, R. K., Werbel, W. A., & Permpalung, N. (2026). Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19. JAMA Network Open, 9(7), e2625591. https://doi.org/10.1001/jamanetworkopen.2026.25591

Vancouver

Srisurapanont K, Manothummetha K, Siriyakorn N, Bowring MG, Li LX, Cochran WV, et al. Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19. JAMA Network Open. 2026;9(7):e2625591. doi:10.1001/jamanetworkopen.2026.25591

BibTeX
@article{Srisurapanont2026,
  author = {Srisurapanont, Karan and Manothummetha, Kasama and Siriyakorn, Nirada and Bowring, Mary G and Li, Lucy X and Cochran, Willa V and Schulz, Cory A and Ellis, Sean and Thammavaranucupt, Kanin and Brennan, Daniel C and Avery, Robin K and Werbel, William A and Permpalung, Nitipong},
  title = {Remdesivir and All-Cause Graft Loss Among Kidney Transplant Recipients With Symptomatic COVID-19},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {7},
  pages = {e2625591},
  doi = {10.1001/jamanetworkopen.2026.25591}
}
Kostenlos starten →